Healionics Corporation, a private medical device company, has announced the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.
Healionics is preparing to commercialize its innovative STARgraft vascular graft.
“We appreciate the strong support in this round by existing shareholders and welcome the participation by several new angel and venture investor groups,” said Mike Connolly, Chief Executive Officer of Healionics.
He added, “We are targeting early next year for commercial launch of STARgraft. This novel synthetic blood vessel, based on our proprietary STAR biomaterial technology, has the potential to improve the lives of dialysis patients by reducing the frequency & severity of infections and the frequency of interventions required to maintain dialysis access.”
